Table 3 Association analysis results for unadjusted and adjusted models of T2D exposure and UF risk limiting to subjects on specific treatments

 T2D (diabetics on Metformin)

3,435

1.12

0.84

1.48

0.450

0.77

0.56

1.05

0.096

 T2D (diabetics on Thiazolidinedione)

3,208

1.36

0.86

2.08

0.161

0.91

0.56

1.48

0.708

 T2D (diabetics on insulin)

3,481

0.71

0.52

0.97

0.032

0.50

0.35

0.70

5.10×10 ⁻⁵

 T2D (diabetics on Metformin)

2,250

0.97

0.65

1.44

0.863

0.70

0.45

1.08

0.104

 T2D (diabetics on Thiazolidinedione)

2,084

1.43

0.85

2.43

0.181

0.91

0.51

1.64

0.757

 T2D (diabetics on insulin)

2,292

0.60

0.38

0.95

0.020

0.42

0.26

0.68

3.54×10 ⁻⁴

 T2D (diabetics on Metformin)

755

1.07

0.68

1.69

0.760

0.78

0.47

1.28

0.329

 T2D (diabetics on Thiazolidinedione)

669

1.24

0.56

2.76

0.597

0.77

0.32

1.90

0.581

 T2D (diabetics on insulin)

764

0.76

0.47

1.22

0.260

0.60

0.36

1.01

0.055